A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL

Inclusion Criteria: * 1\. Age ≥18 years old, male or female; * 2\. No previous treatment for DLBCL, including chemotherapy, targeted therapy and immunotherapy; * 3\. DEL \[Diffuse large B-cell lymphoma with double expression of MYC and BCL2 (immunohistochemical MYC≥40%, BCL2≥50%)\] was confirmed by pathology; Or non-double expression but at least one of the following:; 1. TP53 or other epigenetic gene mutations (as in: ACTB, BCL6, BCOR, CREBBP, EP300, EZH2, HIST1H1C, HIST1H1E, HIST1H2BK, HIST2H2AB, IRF4, KMT2A, KMT2C, KMT2D, MYC, MYD88, NSD2, RAG1, SETD1B SF3B1, SIN3A, TBL1XR1, TET2, TOX, TP53, TRIP12, TRRAP, UBE2A) 2. MYC and BCL2 double hit * 4\. Plan to receive or are receiving a treatment regimen containing tucidinostat (if it is permitted to start using tucidinostat after obtaining specific test results due to pending genetic sequencing results); * 5\. Voluntarily sign informed consent. Exclusion Criteria: * 1\. Patients currently enrolled or planning to participate in any interventional clinical trial; * 2\. The expected survival time is less than 6 months; * 3\. There are any other reasons that the investigators believe are not suitable for patients to participate in this study.

Reproduced word-for-word from the public registry record — the study team can answer questions about it.